Condensed Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 27, 2024	Sep. 29, 2023	Sep. 27, 2024	Sep. 29, 2023
Net sales	$ 505.5	$ 497.0	$ 1,487.6	$ 1,396.6
Cost of sales	284.4	346.2	907.5	1,091.1
Gross profit	221.1	150.8	580.1	305.5
Selling, general and administrative expenses	141.2	129.2	406.0	369.6
Research and development expenses	28.2	25.7	85.3	83.0
Restructuring charges, net	0.1	(0.1)	10.5	0.9
Separation Costs	15.2	142.1	32.2	157.3
Operating income (loss)	36.4	(282.0)	46.1	(441.2)
Interest expense	59.0	133.1	177.5	457.7
Interest income	(7.4)	(3.4)	(20.2)	(12.8)
Other (expense) income, net	(3.8)	9.1	(3.6)	(6.7)
Reorganization items, net	0.0	(1,311.5)	0.0	(1,321.1)
Loss from continuing operations before income taxes	(19.0)	(1,714.1)	(114.8)	(2,213.9)
Income tax expense	7.2	10.8	20.4	508.1
Loss from continuing operations	(26.2)	(1,724.9)	(135.2)	(2,722.0)
Income from discontinued operations, net of income taxes	0.0	0.1	$ 0.3	$ 0.1
Net loss	$ (26.2)	$ (1,724.8)
Basic (loss) income per share (Note 7):
Loss from continuing operations	$ (1.33)	$ (128.61)	$ (6.86)	$ (205.37)
(Loss) income from discontinued operations	0	0	0.02	0.01
Net loss	$ (1.33)	$ (128.60)	$ (6.85)	$ (205.37)
Basic weighted-averaged shares outstanding (in shares)	19.7	13,400,000	19,700,000	13,300,000
Diluted (loss) income per share (Note 7):
Loss from continuing operations	$ (1.33)	$ (128.61)	$ (6.86)	$ (205.37)
(Loss) income from discontinued operations	0	0	0.02	0.01
Net loss	$ (1.33)	$ (128.60)	$ (6.85)	$ (205.37)
Diluted weighted-average shares outstanding (in shares)		13,400,000	19,700,000	13,300,000
Non-restructuring impairment charges	$ 0.0	$ 135.9	$ 0.0	$ 135.9
Retained Earnings (Deficit)
Net loss	$ (26.2)	$ (1,724.8)	$ (134.9)	$ (2,721.9)